SCYNEXIS, Inc.
corporate_fare Company Profile
SCYNEXIS, Inc. (NASDAQ:SCYX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for SCYX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 18 rated 8 or above. Recent SEC coverage for SCYX spans 10-Q, 8-K, 424B3, S-3.
Recent high-impact activity:
- SCYNEXIS Q3 Loss Narrows to $8.5M; $63.2M Cash Funds Operations Into 2029
- SCY-770 Phase 1 Shows Favorable Safety, Phase 2 in ADPKD Set for Q4
- SCYNEXIS Secures Up to $214M BARDA Contract to Advance SCY-247 Antifungal
- BARDA Awards SCYNEXIS Up to $214M Non-Dilutive Funding for SCY-247 Antifungal
- SCYNEXIS Q2: Cash Runway Into 2029, Phase 1 Data for Kidney Disease Drug Due Q3
Financial Snapshot
Short Interest & Short Volume
5.55 days to coverFINRA reported short interest of 450,240 shares in SCYX as of the October 30, 2026 settlement, a 7.1% increase from the prior period — about 5.5 days to cover at its recent average daily volume. On November 20, 2026, 38.2% of SCYX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for SCYX, detected from its recent SEC filings · based on capital-structure filings through 2026-11-05.
Shelf Renewal, Not a Raise · No New Securities or Fees
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →